N-acetylcysteine reduces malondialdehyde levels in chronic hemodialysis patients - A pilot study

Clinical Nephrology

Volumn 59, Issue 6, 2003, Pages 441-446

  Trimarchi, H ^a   Mongitore, M R ^a   Baglioni, P ^a   Forrester, M ^a   Freixas, E A R ^a   Schropp, M ^a   Pereyra, H ^a   Alonso, M ^a  

^a HOSPITAL BRITÁNICO DE BUENOS AIRES   (Argentina)

Author keywords

Atherosclerosis; Chronic renal failure; Glutathione; Hemodialysis; Malondialdehyde; N acetylcysteine; Oxidative stress

Indexed keywords

ACETYLCYSTEINE; FOLIC ACID; IRON SACCHARATE; MALONALDEHYDE; MECOBALAMIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGE; AGED; ANEMIA; ANTIOXIDANT ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; DOSE RESPONSE; DRUG EFFECT; ENDOTHELIUM INJURY; FEMALE; GENDER; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; MALE; OXIDATIVE STRESS; PILOT STUDY; TIME; TREATMENT OUTCOME;

EID: 0038039225     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP59441     Document Type: Article

References (35)

1. Afaq F, Abidi P, Rahman Q 2000 N-acetyl L-cysteine attenuates oxidant-mediated toxicity induced by chrysotile fibers. Toxicol Lett 117: 53-60
2. Arouma OI, Halliwell B, Hoey BM, Butler J 1989 The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide and hyplochlorus acid. Free Radic Biol Med 6: 593-597
3. Bird RP, Draper HH 1984 Comparative studies on different methods of malonaldehyde determination. Methods Enzymol 105: 299-305
4. Bostom AG, Shemin D, Lapane KL 1996 Hyperhomocysteinemia, hyperfibrinogenemia and lipoprotein (a) excess in maintenance dialysis patients: a matched case-control study. Atherosclerosis 125: 91-101
5. Ceballos-Picot I, Witko-Sarsat V, Merad-Boudia M, Nguyen AT, Thevenin M, Jaudon MC, Zingraff J, Jungers P, Deschamps-Latscha B 1996 Glutathione system as a marker of uremia progression and oxidative stress in chronic renal failure. Free Radic Biol Med 21: 845-863
6. Cereser C, Boget S, Parvaz P, Revol A 2001 Thiram-induced cytotoxicity is accompanied by a rapid and drastic oxidation of reduced glutathione with consecutive lipid peroxidation. and cell death. Toxicology 163: 153-162
7. Cheung AK, Sarnak MJ, Yan G 2000 Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 58: 353-362
8. Daschner M, Lenhartz H, Botticher D, Schaefer F, Woll-Schager M, Mehls O, Leichsenring M 1996 Influence of dialysis on plasma lipid peroxidation products and antioxidant levels. Kidney Int 50: 1268-1272
9. De La Fuente M, Victor VM 2001 Ascorbic acid and N-acetylcysteine improve in vitro the function of lymphocytes from mice with endotoxin-induced oxidative stress. Free Radic Res 35: 73-84
10. Deschamps-Latscha B, Witko-Sarsat V 2001 Importance of oxidatively modified proteins in chronic renal failure. Kidney Int 59 (Suppl 78): 108-113
11. Drüeke TB, Nguyen Khoa T, Massy Z, Witko-Sarsat V, Lacour B, Deschamps-Latscha B 2001 Role of oxidized low-density lipoprotein in the atherosclerosis of uremia. Kidney Int 59 (Suppl 78): 114-119
12. Heinecke JW 1996 Atherosclerosis: cell biology and lipoproteins. Curr Opin Lipidol 7: U131-U136
13. Hultqvist M, Hegbrant J, Nilsson-Thorell C, Lindholm T Nilsson P 1997 Plasma concentrations of vitamin C, vitamin E and/or malondialdehyde as markers of oxygen-free radical production during hemodialysis. Clin Nephrol 47: 37-46
14. Janero DR 1990 Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. Free Radic Biol Med 9: 515-540
15. Koh YH, Park YS, Takahasi M, Suzuki K, Taniguchi N 2000 Aldehyde reductase gene expression by lipid peroxidation end products, MDA and HNE. Free Radic Res 33: 739-746
16. Levey AS, Beto JA, Coronado BE 1998 Controlling the epidemic of cardiovascular disease in chronic renal failure: What do we know? What do we need to learn? Where do we go from here? Am J Kidney Dis 32: 853-906
17. Lindner A, Charra B, Sherrard DJ, Scribner BH 1974 Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 290: 697-701
18. Luciak M, Trznadel K 1991 Free oxygen species metabolism during hemodialysis with different membranes. Nephrol Dial Transplant 6: 66-70
19. Navab M, Hamalevy S, Valenten BJ, Fonarow GC, Cardinez GC, Castellani LW, Brennan ML, Lusis AJ, Fogelman AM 1997 Mildly oxidized LDL induces an increased apolipoprotein J/paraxonase ratio. J Clin Invest 99: 2005-2019
20. Nielsen F, Mikkelsen BB, Nielsen JB, Andersen HR, Grand-Jean P 1997 Plasma malondialdehyde as biomarker for oxidative stress: reference interval and effects of life-style factors. Clin Chem 43: 1209-1214
21. Paulsen O, Forsgren A 1989 Effects of N-acetylcysteine on human polymorphonuclear leukocytes. APMIS 97: 115-119
22. Raine AE, Margreiter R, Brunner FP 1992 Report on management of renal failure in Europe, XXII 1991. Nephrol Dial Transplant 7 (Suppl 2): 7-35
23. Ross EA, Koo LC, Moberly JB 1997 Low whole blood and erythrocyte levels of glutathione in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 30: 489-494
24. Ross R 1999 Atherosclerosis: an inflammatory disease. N Engl J Med 340: 115 -126
25. Salonen JT, Ylä-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R, Witzum JL 1992 Autoantibody against oxidized LDL and progression of carotid atherosclerosis. Lancet 339: 883-887
26. Schulz T, Schifel H 1995 Preserved antioxidative defense of lipoproteins in renal failure and during hemodialysis. Am J Kidney Dis 25: 564-571
27. Sies H 1997 Oxidative stress: oxidants and antioxidants. Exp Physiol 82: 291-295
28. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL 1989 Beyond cholesterol modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320: 916-924
29. Steinberg D 1997 Low-density lipoprotein oxidation and its pathobiological significance. J Biol Chem 272: 20963-20966
30. Taccone-Gallucci M, Lubrano R, Belli A, Citti G, Morosetti M, Meloni C, Elli C, Casciani CU 1989 Lack of oxidative damage in serum polyunsaturated fatty acids before and after dialysis in chronic uremic patients. Int J Artif Organs 12: 515-518
31. Urban T, Akerlund B, Jarstrand C, Lindeke B 1997 Neutrophil function and glutathione-peroxidase (GSHpx) activity in healthy individuals after treatment with N-acetyl L-cysteine. Biomed Pharmacother 51: 388-390
32. Vendemiale G, Grattagliano I, Caruso ML, Serviddio G, Valentini AM, Pirrelli M, Altomare E 2001 Increased oxidative stress in dimethylnitrosamine-induced liver fibrosis in the rat: effect of N-acetylcysteine and interferon alpha. Toxicol Appl Pharmacol 175: 130-139
33. Westhuyzen J, Adams CE, Fleming SJ 1995 Evidence for oxidative stress during in vitro dialysis. Nephron 70: 49-54
34. Wheeler DC 1997 Cardiovascular disease in patients with chronic renal failure. Lancet 348: 1673-1674
35. Zager R, Johnson A, Hanson S, Wasse H 2002 Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 40: 90-103